National anti-tuberculosis drug resistance survey, 2002, in Myanmar

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 10, 2006, Pages 1111-1116

  Ti, Ti ^a,d   Lwin, T ^a   Mar, T T ^a   Maung, W ^a   Noe, P ^a   Htun, A ^a   Kluge, H H ^b   Wright, A ^b   Aziz, M A ^b   Paramasivan, C N ^c  

^a National Tuberculosis Programme   (Myanmar)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^d Yangon General Hospital   (Myanmar)

Author keywords

MDR TB; Myanmar; National drug resistance survey; Tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SENSITIVITY; FEMALE; HEALTH SURVEY; HUMAN; ISOLATION PROCEDURE; LUNG DISEASE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYANMAR; PRACTICE GUIDELINE; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTITUBERCULAR; CROSS-SECTIONAL STUDIES; ETHAMBUTOL; FEMALE; HEALTH SURVEYS; HUMANS; ISONIAZID; MALE; MIDDLE AGED; MYANMAR; RIFAMPIN; RISK FACTORS; STREPTOMYCIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 33749459526     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Myanmar National Tuberculosis Programme. Annual report, 2002. Yangon, Myanmar: NTP, 2003.
2. World Health Organization/International Union Against Tuberculosis and Lung Disease. Guidelines for surveillance of drug resistance in tuberculosis. Int J Tuberc Lung Dis 1998; 2: 71-89.
3. Ti T, Htun A, Mu S H, et al. A random sample study of initial drug resistance among tuberculosis cases in Yangon, Myanmar. Yangon, Myanmar: Proceedings of the Myanmar Health Research Congress, 1995.
4. Phyu S, Ti T, Jureen R, et al. Drug-resistant Mycobacterium tuberculosis among new tuberculosis patients, Yangon, Myanmar. Emerg Infect Dis 2003; 9: 274-276.
5. Lwin T. Drug resistance TB in Yangon. (Thesis). Bergen, Norway: University of Bergen, 2004.
6. National Tuberculosis Programme. Annual report, 2003. Yangon, Myanmar: NTP, 2004.
7. Venkataraman P, Paramasivan C N. Bacteriological methods in laboratory diagnosis of tuberculosis. Chennai, India: Tuberculosis Research Centre (ICMR), 1999: 21-23, 34-37.
8. World Health Organization. Treatment of tuberculosis: Guidelines for national programmes. 3rd ed. Geneva, Switzerland: WHO, 2003.
9. Van Rie A, Warren R, Richardson M. Classification of drug resistant tuberculosis in an epidemic area. Lancet 2000; 356: 22-25.
10. Frieden T R, Sterling T, Pablos-Mendez A. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521-526.
11. Espinal M A, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 5: 887-893.
12. World Health Organization/International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis drug resistance in the world. Report no. 3. Third Global report. The WHO/IUATLD Global Report on Anti-Tuberculosis Drug Resistance Surveillance. 1992-2002. Geneva, Switzerland: WHO, 2004.
13. Shah A R, Agarwal S K, Shah K V. Study of drug resistance in previously treated tuberculosis patients in Gujarat, India. Int J Tuberc Lung Dis 2002; 6: 1098-1101.
14. Paramasivan C N, Venkataraman P, Chandrasekaran V. Surveillance of drug resistance in tuberculosis in two districts of South India. Int J Tuberc Lung Dis 2002; 6: 479-484.
15. Toungoussova O S, Caugant D A, Sandven P, Mariandyshev A O, Bjune G. Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia. Int J Tuberc Lung Dis 2002; 6: 406-414.
16. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4 and 6 months of pyrazinamide in 6-month, three-times-weekly regiments for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide. Am Rev Respir Dis 1991; 143: 700-706.
17. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987; 136: 1339-1342.
18. Aung W W, Ti T, Than K K, et al. Study on drug susceptibility patterns of tuberculosis patients attending TB center, Yangon Division with emphasis on those attending private sector before seeking care at public health center. Yangon, Myanmar: Proceedings of the Myanmar Health Research Congress, January 2005.
19. Uplekar M W, Shepard D S. Treatment of tuberculosis by private general practitioners in India. Tubercle 1991; 72: 284-290.
20. Riantawan P, Punnotok J, Chaisuksuwan R, Pransujarit V. Resistance of Mycobacterium tuberculosis to anti-tuberculosis drugs in the central region of Thailand, 1996. Int J Tuberc Lung Dis 1998; 2: 616-620.
21. Kam K M, Yip C W. Surveillance of Mycobacterium tuberculosis drug resistance in Hong Kong, 1986-1999, after the implementation of directly observed treatment. Int J Tuberc Lung Dis 2001; 5: 815-823.
22. Weis S E, Slocum P C, Blais F X, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179-1184.